Armata Pharmaceuticals, Inc. filed its 10-K on Mar 16, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.091 USD | -5.18% | +24.14% | -4.59% |
05-07 | Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000 | MT |
03-21 | Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.59% | 112M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ARMP Stock
- News Armata Pharmaceuticals, Inc.
- Armata Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt